List of Excipients in Branded Drug METHAMPHETAMINE HYDROCHLORIDE

Generic Drugs Containing METHAMPHETAMINE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	methamphetamine hydrochloride	0054-0389	CROSPOVIDONE
Hikma Pharmaceuticals USA Inc	methamphetamine hydrochloride	0054-0389	MAGNESIUM STEARATE
Hikma Pharmaceuticals USA Inc	methamphetamine hydrochloride	0054-0389	MICROCRYSTALLINE CELLULOSE 102
Hikma Pharmaceuticals USA Inc	methamphetamine hydrochloride	0054-0389	POVIDONE K30
Mayne Pharma Commercial LLC	methamphetamine hydrochloride	68308-115	LACTOSE MONOHYDRATE

What are the Most Frequently-Used Excipients in METHAMPHETAMINE HYDROCHLORIDE?

# Of NDCs	Excipient
1	CROSPOVIDONE
2	LACTOSE MONOHYDRATE
1	MAGNESIUM STEARATE
1	MICROCRYSTALLINE CELLULOSE 102
1	POVIDONE K30

Methamphetamine Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Methamphetamine hydrochloride has limited protection at the active-ingredient level because the molecule and salt are decades old. Commercial opportunity is concentrated in reliable immediate-release tablets, differentiated oral dosage forms, supply security, and regulatory execution rather than conventional composition-of-matter patenting. The key constraints are Schedule II controls, a narrow FDA-labeled market, stigma associated with abuse, low expected volume, and the need to demonstrate meaningful clinical or pharmaceutical advantages for any reformulated product.

What is the FDA regulatory status of methamphetamine hydrochloride?

Methamphetamine hydrochloride is an FDA-approved Schedule II central nervous system stimulant marketed in the United States under the brand name Desoxyn. The FDA-approved indications include attention deficit hyperactivity disorder and short-term adjunctive treatment of exogenous obesity when alternative therapies have failed or are clinically inappropriate.[1]

Regulatory attribute	Status
Active ingredient	Methamphetamine hydrochloride
Dosage form	Immediate-release oral tablet
Reference product	Desoxyn
FDA application	NDA 005123
Controlled-substance schedule	Schedule II
Main labeled uses	ADHD; short-term treatment of exogenous obesity
Typical marketed strength	5 mg tablet
Regulatory pathway for a conventional generic	Section 505(j) ANDA
Regulatory pathway for a differentiated formulation	Section 505(b)(2), depending on product design
Biosimilar pathway	Not applicable

The product’s label warns about abuse, misuse, addiction, cardiovascular effects, psychiatric reactions, and growth suppression in pediatric patients.[1] Any commercial product must satisfy controlled-substance manufacturing, storage, recordkeeping, quota, distribution, and diversion-control requirements under the Drug Enforcement Administration framework.[2]

What excipients are used in methamphetamine hydrochloride tablets?

The marketed tablet uses conventional solid-dose excipients associated with immediate-release oral tablets. Public product labeling identifies inactive ingredients such as lactose, corn starch, magnesium stearate, povidone, talc, and related tableting materials, although manufacturers can change excipient systems across approved products and manufacturing sites.[3]

Functional role of the excipients

Excipient class	Commercial function	Key development consideration
Lactose	Diluent and tablet-mass builder	Requires assessment for lactose intolerance, hydrate state, and supplier consistency
Corn starch	Filler and disintegrant	Supports breakup and drug release in immediate-release tablets
Povidone	Binder	Improves granule and tablet strength
Magnesium stearate	Lubricant	Excessive levels or blending can slow dissolution
Talc	Glidant or anti-adherent	Requires control of particle characteristics and regulatory quality
Colloidal silicon dioxide, where used	Glidant and flow aid	Improves powder handling and compression consistency
Crospovidone or sodium starch glycolate, where used	Superdisintegrant	Can support rapid disintegration in low-dose tablets
Film-coating polymers	Identification, protection, swallowability	May provide moisture protection without materially delaying release

The 5 mg strength creates a dose-uniformity challenge. Methamphetamine hydrochloride is present at a low percentage of total tablet weight when standard diluent levels are used. Content uniformity therefore depends on API particle-size distribution, geometric dilution, granulation control, blend segregation management, and validated sampling.

How should an excipient strategy be designed for methamphetamine hydrochloride?

The most commercially defensible strategy is a simple, robust immediate-release formulation with low manufacturing complexity and strong supply continuity.

Direct compression versus wet granulation

Direct compression can reduce process steps and avoid water exposure. It is attractive when the API has acceptable flow, compressibility, and blend uniformity. The principal risks are segregation and low-dose content-uniformity failures.

Wet granulation can improve blend uniformity, flow, and tablet strength. It introduces additional equipment, drying controls, residual-moisture risk, and potential API migration. A development program should compare both approaches using:

• assay and content-uniformity data;
• disintegration and dissolution profiles;
• blend segregation studies;
• tablet friability and hardness;
• moisture uptake;
• accelerated and long-term stability;
• scale-up reproducibility.

For a low-volume controlled substance, direct compression may have the better cost profile if it meets uniformity and dissolution requirements. Wet granulation may be justified where API flow or dose distribution is poor.

Target product profile

A practical generic target product profile includes:

Attribute	Preferred target
Dosage form	Immediate-release tablet
Strength	5 mg, with additional strengths assessed only if market demand supports them
Release	Rapid and reproducible immediate release
Manufacturing	Direct compression or low-complexity granulation
Packaging	Unit-dose or high-barrier bottle packaging
Stability	Protection from moisture, heat, and light
Identification	Differentiated color, shape, imprint, and packaging
Excipient profile	Familiar, compendial, broadly sourced excipients
Commercial objective	Low cost, low batch failure risk, controlled inventory

Because methamphetamine hydrochloride is highly potent relative to the tablet dose, manufacturers should avoid unnecessary excipient complexity. Each additional excipient creates supplier qualification, compatibility, labeling, and change-control obligations without necessarily creating market value.

Taste masking and patient acceptability

Taste masking has limited value for a conventional swallowed tablet but becomes relevant for orally disintegrating, chewable, liquid, or multiparticulate products. Methamphetamine hydrochloride is water soluble, so taste masking may require ion-exchange resins, polymer coatings, lipid barriers, or encapsulated granules.

These technologies can increase manufacturing cost and may alter dose release. A taste-masked product would need comparative dissolution and, depending on the formulation and regulatory pathway, additional pharmacokinetic or clinical support.

What formulation patents could protect methamphetamine hydrochloride products?

The active ingredient is unlikely to support meaningful new composition-of-matter protection. Patent value would instead come from formulation, delivery, manufacturing, packaging, or abuse-deterrence claims.

Potential patent categories

Patent category	Possible claim scope	Commercial value
Modified release	Extended-release matrix, coated beads, osmotic system	Potentially high, but requires clinical differentiation
Abuse deterrence	Physical or chemical resistance to crushing, extraction, or injection	Potentially high, but difficult to validate and commercialize
Taste masking	Coated particles, ion-exchange complexes, polymer barriers	Moderate, mainly for pediatric or orally disintegrating products
Orally disintegrating tablet	Rapid disintegration with controlled palatability	Moderate
Multiparticulate delivery	Sprinkle capsules, coated granules, or sachets	Moderate
Transdermal or implantable delivery	Sustained systemic exposure	High technical and regulatory burden
Manufacturing process	Low-segregation blending, granulation, or continuous manufacture	Moderate, with enforcement limitations
Packaging	Unit-dose diversion control or tamper-evident systems	Usually limited unless tied to a broader system

Any new patent strategy should claim a measurable technical result, such as a defined dissolution profile, reduced dose dumping, reduced extraction, improved content uniformity, or enhanced stability. Broad claims covering methamphetamine hydrochloride plus routine excipients would face substantial validity and obviousness risk.

When does methamphetamine hydrochloride lose exclusivity?

The original active-ingredient and product exclusivity periods expired long ago. Methamphetamine hydrochloride was approved before the modern Hatch-Waxman framework, and the reference product does not depend on current new-chemical-entity exclusivity.

The exclusivity profile is therefore different from that of a recently approved small-molecule drug:

Protection type	Status
Composition-of-matter patent	Expired or commercially obsolete
Original NDA exclusivity	Expired
Orphan-drug exclusivity	Not applicable
Biosimilar exclusivity	Not applicable
Pediatric exclusivity	No current basis identified for the legacy product
New formulation protection	Available only through separately patentable innovation
Generic challenge protection	Potential 180-day exclusivity for a qualifying first ANDA applicant

A new formulation could receive three to five years of FDA regulatory exclusivity in limited circumstances if approved through the applicable statutory pathway and satisfies the relevant requirements. That period would attach to the qualifying new product, not revive exclusivity for the old immediate-release tablet.[4]

What is the Orange Book status of Desoxyn?

The Orange Book identifies FDA-approved drug products, therapeutic equivalence evaluations, and certain patents and exclusivity information.[5] For methamphetamine hydrochloride, the relevant reference product is Desoxyn under NDA 005123.

The principal Orange Book questions for a generic developer are:

1. Whether the reference product has an active therapeutic-equivalence listing.
2. Whether any patents are listed against the reference product.
3. Whether any exclusivity remains active.
4. Whether a proposed product can match the reference product’s dosage form, strength, route, and labeling.
5. Whether a Paragraph IV certification is required.

Because the underlying drug is old, the primary regulatory risk is usually not an active compound patent. The risk is product-specific: availability of the reference listed drug, FDA expectations for bioequivalence, controlled-substance manufacturing capacity, and commercial access to a small and concentrated prescriber base.

How do Paragraph IV challenges apply to methamphetamine hydrochloride?

A Paragraph IV certification is relevant only if the Orange Book lists an unexpired patent for the reference product. A generic applicant asserting that a listed patent is invalid, unenforceable, or not infringed can trigger statutory notification and potential patent litigation.[4]

For a legacy methamphetamine hydrochloride tablet, the likely scenarios are:

Scenario	Consequence
No active listed patent	ANDA proceeds without Paragraph IV patent litigation
Active formulation patent	Applicant may use Paragraph III, Paragraph IV, or a label carve-out strategy
Method-of-use patent	A section viii statement may be available if the patented use can be carved from labeling
Newly patented 505(b)(2) product	Follow-on products may face listed-patent certification requirements
First qualifying ANDA	Potential 180-day generic exclusivity

Method-of-use patents are particularly relevant because the approved uses include ADHD and obesity. A generic applicant may seek a skinny label excluding a patented indication, subject to FDA and patent-law requirements.

What manufacturing and intellectual-property barriers exist?

The strongest barriers are operational rather than chemical.

Controlled-substance manufacturing

A manufacturer must manage:

• DEA registration and Schedule II controls;
• procurement quota;
• secure storage and restricted access;
• batch and inventory reconciliation;
• suspicious-order monitoring;
• diversion prevention;
• specialized distribution controls;
• destruction and recall procedures.

A small API supply base can create additional risk. A commercial entrant needs qualified suppliers with reliable methamphetamine hydrochloride production, appropriate regulatory documentation, and the ability to support a controlled-substance audit trail.

Product-quality barriers

Low-dose tablets can fail because of:

• blend segregation;
• API hot spots;
• variable particle-size distribution;
• lubricant overmixing;
• dissolution drift;
• moisture-related degradation or physical change;
• tablet identification and packaging errors.

These risks favor a formulation with a narrow excipient set, redundant suppliers, and a process that can be transferred across manufacturing sites.

Which commercial opportunities are available?

The largest opportunity is a reliable generic or authorized-generic supply position, not a premium excipient product.

Opportunity ranking

Opportunity	Market potential	Development risk	Patent potential
Conventional 5 mg generic tablet	Moderate	Low to moderate	Low
Authorized generic or contract supply	Moderate	Moderate	Low
Orally disintegrating tablet	Small to moderate	Moderate	Moderate
Pediatric taste-masked product	Small	Moderate to high	Moderate
Extended-release product	Moderate	High	High
Abuse-deterrent formulation	Uncertain	High	High
Specialty packaging and unit-dose system	Small	Low to moderate	Low to moderate
Alternate dosage form for obesity	Uncertain	High	Moderate to high

A conventional generic can compete on availability, consistent supply, tablet quality, and distribution. A novel product must justify higher development costs through adherence, reduced misuse, longer dosing intervals, or a clinically meaningful patient benefit.

How does methamphetamine hydrochloride compare with competing stimulants?

Methamphetamine hydrochloride competes with amphetamine mixed salts, dextroamphetamine, lisdexamfetamine, methylphenidate products, and nonstimulant ADHD medicines. These alternatives generally have larger prescriber familiarity, broader commercial infrastructure, or more established pediatric and adult market positions.

Product class	Relative commercial position	Implication
Methamphetamine hydrochloride	Narrow, highly controlled niche	Supply reliability may matter more than formulation novelty
Mixed amphetamine salts	Broad ADHD use and multiple dosage forms	Difficult direct commercial displacement
Lisdexamfetamine	Prodrug positioning and established brand equity	Strong competitor for abuse-conscious prescribing
Methylphenidate	Large generic and branded ecosystem	High substitution pressure
Nonstimulants	No Schedule II control for some products	Relevant where misuse risk limits stimulant use

A methamphetamine hydrochloride product with a new delivery profile would need to compete against established extended-release stimulants, not only against Desoxyn.

What is the revenue exposure and generic launch risk?

Revenue exposure is likely concentrated in a small number of manufacturers, distributors, specialty pharmacies, and prescriber networks. Public company revenue disclosures often do not separate Desoxyn or methamphetamine hydrochloride sales from broader pharmaceutical portfolios, which limits product-level revenue analysis.

The commercial risk profile is asymmetric:

• The addressable market is narrow.
• A shortage can create temporary pricing power.
• Chronic supply interruptions can cause rapid prescriber switching.
• Controlled-substance quota limits can restrict upside.
• Generic entry may reduce price but may not create a large absolute market.
• A single manufacturing or regulatory event can materially affect availability.

A generic launch is most plausible when the applicant can secure API supply, obtain DEA quota, demonstrate bioequivalence efficiently, and avoid excessive launch inventory. Launching multiple strengths or a complex formulation would increase regulatory and supply risk without clear evidence of sufficient demand.

Key Takeaways

• Methamphetamine hydrochloride has no meaningful remaining composition-of-matter exclusivity.
• The commercial reference product is Desoxyn, an FDA-approved Schedule II immediate-release tablet.
• Conventional excipients such as lactose, starch, povidone, magnesium stearate, and talc support a low-complexity generic strategy.
• The main formulation challenge is dose uniformity at the 5 mg strength.
• The strongest commercial opportunity is a dependable generic or authorized-generic supply position.
• Novel value may come from extended release, abuse deterrence, taste masking, multiparticulates, or pediatric delivery systems.
• Patent value will depend on measurable formulation or manufacturing performance, not routine excipient substitution.
• Controlled-substance compliance, quota, diversion control, and API supply are major commercial barriers.
• Biosimilar risk is irrelevant because methamphetamine hydrochloride is a small molecule.
• Paragraph IV litigation depends on whether the current Orange Book record contains an active listed patent for the reference product.

FAQs

Can methamphetamine hydrochloride be reformulated as an extended-release product?

Yes. An extended-release product could be developed through an NDA supplement, 505(b)(2) application, or another appropriate pathway depending on the product and reference framework. It would require comparative pharmacokinetic and dissolution data and could support formulation patent claims.

Are lactose-free methamphetamine hydrochloride tablets commercially attractive?

Potentially, but the opportunity is niche. A lactose-free product could address excipient intolerance or institutional formulary preferences, although the change alone would likely provide limited patent protection and modest pricing power.

Can an orally disintegrating methamphetamine tablet avoid Schedule II controls?

No. The dosage form does not change the active ingredient’s controlled-substance classification. The product would remain subject to Schedule II requirements.

Is an abuse-deterrent methamphetamine hydrochloride product likely to receive FDA labeling?

Only if the product satisfies FDA’s abuse-deterrent evaluation standards and demonstrates that its formulation meaningfully reduces abuse through one or more routes of manipulation. Abuse deterrence does not eliminate addiction or misuse risk.

What is the strongest patent strategy for a new methamphetamine hydrochloride product?

The strongest strategy would combine a defensible delivery technology with measurable performance claims, such as controlled exposure, reduced dose dumping, resistance to extraction, improved content uniformity, or clinically meaningful adherence benefits.

References

1. U.S. Food and Drug Administration. (2024). Desoxyn (methamphetamine hydrochloride) tablets: Prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/

2. U.S. Drug Enforcement Administration. (2024). Controlled substances act. https://www.deadiversion.usdoj.gov/

3. National Library of Medicine. (2024). Desoxyn, methamphetamine hydrochloride tablet: Drug label information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/

4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application approvals and patent certifications. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book